Paper Details

  1. Home
  2. Paper Details

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.

Author: , DarlingJama M, Di BisceglieAdrian, DongMeichen, EvonDonna M, FishbeinDawn A, FriedMichael W, HinestrosaFederico, HornePatrick M, KhaliliMandana, KixmillerScott, LokAnna S, MichaelLarry, MoonJuhi S, MorelliGiuseppe, MuirAndrew J, NelsonDavid R, PearlmanBrian, PeterJoy, Rajender ReddyK, SegalJodi B, ShermanKenneth E, ShiffmanMitchell L, SloanAnquenette, StewartPaul W, SulkowskiMark S, VainoriusMonika, WadsworthSummer

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Pragmatic Clinical TrialA trial conducted in a real-world clinical setting. It evaluates the effectiveness of interventions in everyday healthcare environments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ledipasvir/sofosbuvir and elbasvir/grazoprevir were equally effective in treating HCV genotype 1, with high sustained viral response rates and few adverse effects. Both regimens are supported by current guidelines.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: Multiple direct-acting antiviral (DAA) regimens are available to treat HCV genotype 1 infection. However, comparative effectiveness from randomized controlled trials of DAA regimens is unavailable. APPROACH AND RESULTS: We conducted a pragmatic randomized controlled trial (NCT0...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/34255381

データ提供：米国国立医学図書館（NLM）

Prioritizing Patient Care: A Pragmatic Approach to Hepatitis C Treatment

This pragmatic randomized controlled trial (NCT02786537) aimed to compare the effectiveness of different direct-acting antiviral (DAA) regimens for treating chronic hepatitis C. The researchers adopted a pragmatic approach, mirroring real-world clinical practice, in their quest to find the most effective treatment options for patients.

DAAs: A Promising Front in the Battle Against Hepatitis C

The study found that both ledipasvir/sofosbuvir (LDV/SOF) and elbasvir/grazoprevir (EBR/GZR) achieved high sustained viral response rates at 12 weeks (SVR12), indicating their effectiveness in eradicating the virus. These findings reinforce the ongoing success of DAAs in the fight against hepatitis C, offering a beacon of hope in the vast desert of viral infections.

Navigating the Hepatitis C Treatment Landscape

The study's findings provide valuable insights for clinicians managing patients with hepatitis C, underscoring the importance of choosing treatment regimens based on individual patient needs and preferences. Just as a desert nomad chooses the optimal path through shifting sands, clinicians must navigate the complexities of hepatitis C treatment to ensure optimal patient outcomes.

Dr.Camel's Conclusion

The PRIORITIZE study highlights the importance of pragmatic research in finding effective treatments for complex diseases. It reminds us that we must always strive to improve our understanding of diseases and develop more targeted therapies that can effectively address individual patient needs.
Date :
  1. Date Completed 2022-01-14
  2. Date Revised 2022-12-02
Further Info :

Pubmed ID

34255381

DOI: Digital Object Identifier

NIHMS1752507

Related Literature

Article Analysis
・Effects of elbasvir and grazoprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.